Galmed Pharmaceuticals Receives Nasdaq Delisting Warning for Minimum Bid Price Non-Compliance

summarizeSummary

Galmed Pharmaceuticals Ltd. announced it received a letter from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Nasdaq Minimum Bid Price Notification

  Galmed Pharmaceuticals Ltd. received a letter from Nasdaq Listing Qualifications indicating non-compliance with the minimum bid price requirement of $1.00 per share.

• 180-Day Compliance Period

  The company has 180 calendar days, until July 28, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

• Potential Delisting Risk

  Failure to regain compliance within the initial period could lead to notification of delisting, though an additional compliance period may be possible under certain conditions.

auto_awesomeAnalysis

Galmed Pharmaceuticals Ltd. has received a formal notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, as its shares have traded below $1.00 for 30 consecutive business days. This is a critical development for the company, especially given its current stock price of $0.7063, which is near its 52-week low. The company now has 180 calendar days, until July 28, 2026, to regain compliance by having its ordinary shares close at or above $1.00 for at least ten consecutive business days. Failure to do so could lead to delisting from The Nasdaq Capital Market, which would significantly impair its ability to raise capital, reduce liquidity for investors, and diminish its public profile. For a clinical-stage biopharmaceutical company, maintaining a Nasdaq listing is crucial for funding ongoing research and development.